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Abstract
Virus-like particles (VLPs) consist of capsid proteins from viruses and have been shown to be usable as carriers of protein
and peptide antigens for immune therapy. In this study, we have produced and assayed murine polyomavirus (MPyV) VLPs
carrying the entire human Prostate Specific Antigen (PSA) (PSA-MPyVLPs) for their potential use for immune therapy in a
mouse model system. BALB/c mice immunized with PSA-MPyVLPs were only marginally protected against outgrowth of a
PSA-expressing tumor. To improve protection, PSA-MPyVLPs were co-injected with adjuvant CpG, either alone or loaded
onto murine dendritic cells (DCs). Immunization with PSA-MPyVLPs loaded onto DCs in the presence of CpG was shown to
efficiently protect mice from tumor outgrowth. In addition, cellular and humoral immune responses after immunization
were examined. PSA-specific CD4
+ and CD8
+ cells were demonstrated, but no PSA-specific IgG antibodies. Vaccination with
DCs loaded with PSA-MPyVLPs induced an eight-fold lower titre of anti-VLP antibodies than vaccination with PSA-MPyVLPs
alone. In conclusion, immunization of BALB/c mice with PSA-MPyVLPs, loaded onto DCs and co-injected with CpG, induces
an efficient PSA-specific tumor protective immune response, including both CD4
+ and CD8
+ cells with a low induction of
anti-VLP antibodies.
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Introduction
Prostate cancer is the second most frequently diagnosed cancer
in men globally, with 782 600 new cases and an estimated 254 000
deaths in 2007 [1]. If the cancer is detected early and is localized
within the prostatic capsule, it can be cured by surgery or
radiotherapy. However, the prognosis is often poor if metastasis
has already occurred at the time of diagnosis, with an average
survival of 2.5 years [2,3]. The mainstay of therapy for metastatic
prostate cancer is androgen ablation accomplished by either
androgen-antagonistic agents or castration [4]. Although andro-
gen withdrawal prolongs the period free of disease progression,
prostate tumor cells eventually become independent of androgen,
resulting in relapse [5,6]. Despite major advances in the treatment
of prostate cancer during the last decades, current therapies are
usually debilitating, causing impotence and incontinence resulting
in low quality of life for the patient. Consequently, there is a need
for new and less damaging treatments and immunotherapy might
represent one such strategy.
Current immunotherapeutic strategies against prostate cancer
include administration of antibodies [7–9] and different kinds of
cancer vaccines, for example administration of peptides derived
from prostate antigen proteins [10], whole tumor cells [11],
dendritic cells (DCs) loaded with peptides [12] or tumor cell lysates
[13], and DNA encoding human Prostate Specific Antigen (PSA)
[14]. Some of these developments are promising. However, it is
probable that additional approaches are necessary to combat
metastatic prostate cancer.
PSA is a chymotrypsin-like serine protease that has a highly
restricted tissue distribution and is expressed in the epithelial cells
of the prostate gland, thus in the same cell type from which most
prostate tumors arise [15]. Its expression is regulated by androgen,
and it is present at extremely low levels in the circulation of adult
men [16]. Most prostate tumors, even the poorly differentiated
ones, continue to express and release PSA [17]. Thus, PSA is
widely used as a serum marker for prostate cancer [18]. The
almost exclusive tumor specific expression of PSA makes it a
potential target antigen for anti-tumor cytotoxic T lymphocytes
(CTLs). In addition, detection of anti-PSA antibodies and
circulating CD8
+ T cells in patients with advanced prostate
cancer indicates that PSA can be the target of an autoimmune
response and that tolerance to PSA is not absolute [19–23].
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capsid proteins from viruses such as papillomavirus, rotavirus and
polyomavirus [24–26]. These particles have been shown to be
exploitable for vaccination against viral infection, where the best-
known examples are the VLP based vaccines against various types
of Human Papilloma Virus [27,28]. In addition, VLPs have also
been used as carriers of foreign genetic material or protein and
peptide antigens for gene and immune therapy. More specifically,
chimeric VLPs, carrying tumor antigens fused to capsid proteins,
have successfully been used to prevent outgrowth of tumors in
several mouse models [29–31]. Furthermore, our group has
previously shown that VLPs from murine polyomavirus
(MPyVLPs) carrying the breast cancer antigen Her2 (Her2-
MPyVLPs) can protect mice from outgrowth of the Her2-
expressing murine tumor cell D2F2/E2, as well as spontaneous
tumor formation in transgenic BALB-neuT mice [29]. In the same
system, it was also shown that co-injection of Her2-MPyVLPs with
adjuvant CpG, or loading of Her2-MPyVLPs onto DCs could
improve the efficiency of these vaccines [32–34].
In this study, we produced MPyVLPs carrying human full-
length PSA (PSA-MPyVLPs) and explored the possibility to use
these VLPs in an experimental model to immunize BALB/c mice
and protect them from outgrowth of the PSA-expressing tumor
D2F2/PSA. To enhance protection, we also co-injected PSA-
MPyVLPs with adjuvant CpG, in combination with loading them
onto murine DCs in vitro before immunization. Finally, cellular and
humoral immune responses were examined after the different
immunization protocols.
Materials and Methods
Ethics Statement
The animal experiments in this study were conducted according
to Ethical permissions N357/07 and N351/09 from Stockholms
Norra Djurfo ¨rso ¨ksetiska Na ¨mnd, Sweden. All efforts were made to
minimize suffering.
Construction, purification and characterization of
MPyVLPs and PSA-MPyVLPs
The VP1 gene from MPyV (from pPYwt [35]) was cloned under
the p10 promoter in the baculovirus transfer vector pAcDB3 (BD
Biosciences Pharmingen, San Diego, CA) as described earlier [29].
The PSA gene (from pVAX-PSA [14]) was fused via an alanine
linker to the 306 C-terminal nucleotides of VP2/VP3 from MPyV
and cloned under the polyhedrin promoter in the same plasmid.
Recombinant baculoviruses were produced and generation and
purification of VLPs from these baculoviruses were performed as
described earlier [29], here using a PSA specific immunoblot with
a polyclonal rabbit anti-human PSA antibody (DakoCytomation,
Glostrup, Denmark). MPyVLPs were produced as described
previously [29]. The morphology of the purified VLPs was
analysed by electron microscopy as described earlier [36]. The
approximate number of VP2/3-PSA molecules per PSA-MPyVLP
was estimated using an immunoblot including a serial dilution of
human recombinant PSA (Fitzgerald Industries International,
North Acton, USA).
Mice
Female BALB/c mice, aged 6–10 weeks, were bred and
maintained at the Dept. of Microbiology, Tumor and Cell
Biology, Karolinska Institutet.
Cell line
The murine mammary cell line D2F2 (H-2
d) was co-transfected
with pVAX-PSA [14] expressing full length human PSA and
pcDNA3 expressing the neomycin resistance gene, using Lipo-
fectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s instructions, to obtain a PSA
positive H-2
d cell line. Cells were selected, cloned and analysed for
expression of PSA by immunoblot. One clone (D2F2/PSA) with a
strong PSA expression was selected for use for in vivo experiments.
D2F2/PSA cells were cultured as previously described for D2F2/
E2 [32].
Figure 1. Characterization of PSA-MPyVLPs. (A) Immunoblot
using a polyclonal rabbit anti-human PSA antibody showing the VP2/3-
PSA fusion protein as a band of approximately 41 kDa. We also see a
smaller fusion protein of approximately 25 kDa, probably due to
alternative splicing or post-translational proteolytic cleavage. Lane 1:
Protein Ladder, Lane 2: PSA-MPyVLPs. (B) Electron microscopy showing
PSA-MPyVLPs with an approximate diameter of 45 nm.
doi:10.1371/journal.pone.0023828.g001
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For in vitro experiments the following proteins and peptides were
used: human recombinant PSA (Fitzgerald Industries International,
North Acton, USA), Human Serum Albumin (HSA) (Octapharma
AB, Stockholm, Sweden), Phytohaemagglutinin (PHA) (Sigma-
Aldrich Sweden AB, Stockholm, Sweden), PSA immunodominant
CD4-restricted peptide PSA238-253 (ERPSLYTKVVHYRKWI), and
PSA immunodominant CD8-restricted peptide PSA188-197
(HPQKVTKFML) [37] (both from ProImmune, Oxford, UK).
As a negative control the LCMV-derived peptide NP118-126
(RPQASGVYM) (Genscript Corporation, New Jersey, USA) was
used. As a positive control phorbol myristate (PMA) together with
ionomycin (IO) (Sigma-Aldrich Sweden AB, Stockholm, Sweden)
was used.
Purification of murine DCs and loading with VLPs
Murine spleen derived DCs were isolated using CD11c
MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and
loaded with VLPs as previously described [32]. Briefly, murine
spleens were digested with 2 mg/ml collagenase type D (Roche
Diagnostics), labelled with anti-CD11c magnetic beads and
enriched on MACS columns according to manufacturer’s
protocol. CD11c
+ DCs, 2610
5 per animal to be vaccinated, were
then incubated with human recombinant PSA (2 mg), MPyVLPs
or PSA-MPyVLPs (50 mg) one hour on ice, and washed twice.
Immunization and tumor cell challenge
For in vivo tumor rejection tests ten BALB/c mice per group
were immunized with a single subcutaneous injection in the flank
of 50 mg PSA-MPyVLPs, or MPyVLPs as a negative control, or
2 mg human recombinant PSA (corresponding to the approximate
amount of PSA in 50 mg PSA-MPyVLPs), with or without 50 mg
CpG 1826 (InvivoGen, San Diego, CA, USA) as adjuvant, and
when indicated loaded onto 2610
5 DCs. Two weeks later mice
were injected with 5610
4 D2F2/PSA cells subcutaneously in the
flank. The incidence and growth of tumors were measured twice
weekly by measuring three diameters, to establish tumor volume.
Mice were sacrificed when the tumor diameter reached 10 mm in
any dimension.
For in vitro assays three mice per group were immunized in the same
way as above and sacrificed one week later to harvest the splenocytes.
Enzyme-Linked Immunosorbent Spot Assay (ELISpot)
An IFNc ELISpot was performed according to the manufac-
turer’s instructions (Mabtech, Nacka, Sweden). Briefly, splenocytes
(1.2610
5) were cultured in triplicates for 20 hours in ELISpot
plates coated with an anti-mouse IFNc antibody, alone or together
with 5 mg/ml recombinant PSA, PSA238-253, PSA188-197,o r
NP118-126 as negative control, or 25 ng/ml PMA together with
250 ng/ml IO as positive control. Spots were detected and
counted in an ELISpot reader (AID, Strassberg, Germany).
Intracellular IFNc staining and proliferation assay
Analysis of intracellular IFNc production in PSA-specific CD4
+
and CD8
+ cells after immunization was performed as previously
described [38]. In short, splenocytes from mice were stimulated
with 5 mg/ml PSA238-253, PSA188-197,N P 118-126 as negative
control, or 25 ng/ml PMA together with 250 ng/ml IO as
positive control, and incubated at 37uC for 5 days. Thereafter,
splenocytes were collected and subjected to a second stimulation
with the same stimuli as above for 4 hours. Brefeldin A was added
after 2 hours, followed by surface staining of CD4 or CD8 and
intracellular staining for IFNc. Cells were then analysed using flow
cytometry.
Analysis of proliferation of CD4
+ and CD8
+ cells after
immunization was performed using the APC BrdU Flow Kit
according to the manufacturer’s protocol (BD Biosciences
Pharmingen, San Diego, CA, USA). Briefly, splenocytes were
cultured together with 5 mg/ml recombinant PSA, 2.5 mg/ml
HSA as negative control, or 10 mg/ml PHA as positive control,
and incubated at 37uC for 72 hours. 1 mM BrdU (thymidine
analogue) was added to all cells and incubated at 37uC overnight.
Cells were thereafter stained for intracellular BrdU and surface
CD4 or CD8, and analysed using flow cytometry.
Flow cytometry
Flow cytometry was performed on a FACSCalibur with
CellQuest Pro software (BD Biosciences Pharmingen, San Diego,
CA, USA) using directly conjugated mAbs against the following
markers: PE anti-mouse IFNc, FITC anti-mouse CD4, PE anti-
mouse CD4, FITC anti-mouse CD8, APC anti-mouse CD8 and
APC anti-BrdU (all from BD Biosciences Pharmingen, San Diego,
CA, USA).
Table 1. Tumor outgrowth in BALB/c mice.
Immunogen Exp.1 Exp.2 Exp.3 Exp.4 Exp.5 Exp.6 Exp.7 Total takes % p value
a
Non-immunized 10/10 9/10 9/10 5/10 5/10 10/10 7/10 55/70 79 ref.
MPyVLPs + CpG 10/10 10/10 100 ns
b
MPyVLPs/DC + CpG 10/10 6/10 16/20 80 ns
c
PSA/DC + CpG 4/10 4/10 40 ns
d
PSA-MPyVLPs 6/10 7/10 2/10 15/30 50 ,0.01
e
PSA-MPyVLPs + CpG 5/10 6/10 5/10 4/10 3/10 23/50 46 ,0.05
f
PSA-MPyVLPs/DC + CpG 2/10 0/10 4/10 0/10 6/40 15 ,0.001
g
aCompared to non-immunized mice according to respective grouping
bExp. 3,
cExp. 6 and 7,
dExp. 7,
eExp. 1, 2 and 7,
fExp. 2–5 and 7,
gExp. 4-7.
doi:10.1371/journal.pone.0023828.t001
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Mouse sera, collected 13 days after immunization from tail
veins, were analysed for presence of anti-VP1 and anti-PSA IgG
antibodies using an ELISA as previously described [32]. Briefly,
microtiter plates were coated with 5 mg/ml MPyVLPs or
recombinant PSA. Sera were added, as well as a mouse anti-
human PSA antibody (DakoCytomation, Glostrup, Denmark) as
positive control for the PSA-ELISA, and after one-hour incuba-
tion, and washing, secondary alkaline phosphatase-conjugated
goat anti-mouse IgG (Sigma-Aldrich Sweden AB, Stockholm,
Sweden) was added for one hour. Plates were developed with
nitrophenylphosphate tablets (Sigma-Aldrich Sweden AB, Stock-
holm, Sweden) and absorbance was measured at 405 nm.
Statistical analyses
Differences in tumor takes were analysed by Fisher’s exact two-
tailed test. Student’s t-test was used to analyse differences in in vitro
stimulation, proliferation, ELISpot and ELISA data.
Results
Construction and characterization of MPyVLPs carrying a
VP2/3-PSA fusion protein
Virus-like particles consisting of full-length MPyV VP1 and a
fusion protein between the complete PSA protein and the 102
C-terminal amino acids of the VP2/VP3 protein (denoted PSA-
MPyVLPs) were produced using a baculovirus transfection
vector system. PSA-MPyVLPs were analysed on immunoblot
(Figure 1A) and demonstrated to contain the VP2/3-PSA fusion
protein besides VP1. The purified PSA-MPyVLPs also turned
out to contain a smaller protein, also recognized by the anti-PSA
antibody, with a size of approximately 25 kDa (Figure 1A). This
protein most likely represents a shorter version of the VP2/3-
PSA protein produced either by alternative splicing or post-
translational proteolytic cleavage. Electron microscopy showed
VLPs with a diameter of approximately 45 nm (Figure 1B). The
number of VP2/3-PSA molecules per PSA-MPyVLP was
Figure 2. Tumor outgrowth in BALB/c mice. Illustration of experiments 3 and 6, (A) and (B) respectively, according to Table 1.
doi:10.1371/journal.pone.0023828.g002
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PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23828Figure 3. IFNc-secretion from PSA-specific cells. ELISpot analysis. (A and B) Splenocytes stimulated with recombinant PSA. Significantly more
PSA-specificsecretionofIFNc was inducedafterimmunization withPSA-MPyVLPs alone(p,0.05),PSA-MPyVLPsonDCs(p,0.01),andPSA-MPyVLPson
DCs with CpG (p ,0.01) as compared to non-immunized mice. (C) Splenocytes stimulated with PSA immunodominant CD4- or CD8 restricted peptides.
PSA-MPyVLP immunization induced both PSA-specific CD4
+ (p ,0.01) and CD8
+ cells (p ,0.05). Loading of PSA-MPyVLPs onto DCs resulted in
production of PSA-specific CD8
+ cells (p ,0.05). Shown are representative bar-graphs from three experiments with three mice in each group. Values
from non-stimulated cells have been subtracted. Error bars represent S.D. p values calculated using Student’s t-test (* = p,0.05, ** = p,0.01).
doi:10.1371/journal.pone.0023828.g003
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dilution of human recombinant PSA on an immunoblot (data
not shown). Thus when immunizing mice with around 50 mgo f
PSA-MPyVLPs, approximately 2 mg of PSA protein was
included.
DCs loaded with PSA-MPyVLPs and co-injected with CpG
protect BALB/c mice against outgrowth of a PSA-
expressing tumor
To test if PSA-MPyVLPs could induce protective immunity,
seven experiments with ten mice per group, receiving different
vaccination combinations, were performed and the data are
summarized in Table 1, while two representative experiments are
shown in Figure 2. In all experiments each mouse was only
vaccinated once. Two weeks after immunization mice were
challenged with a lethal dose of PSA-positive D2F2/PSA cells
and monitored for tumor outgrowth.
When summarizing all in vivo data (Table 1), immunization with
PSA-MPyVLPs alone resulted only in a weak protection against
outgrowth of PSA-expressing D2F2/PSA tumor cells, with a 50%
tumor take as compared to 79% in non-immunized mice
(p,0.01). Co-injection of PSA-MPyVLPs and CpG resulted in a
protective effect with a 46% tumor take (p,0.05), while loading of
PSA-MPyVLPs onto DCs and co-injecting with CpG further
reduced the tumor take to 15% (p,0.001) (Table 1). Furthermore,
vaccinating with PSA-MPyVLPs loaded on DCs with CpG was
significantly more efficient as compared to vaccinating with either
PSA-MPyVLPs alone (p,0.01), or together with CpG (p,0.01),
while there was no significant difference between the latter two
(data not shown). Immunization with human recombinant PSA in
combination with CpG and DCs resulted in a 40% tumor take
(p=ns) (Table 1). Statistical analyses for the respective immuni-
zation groups are presented in Table 1. Protection was PSA-
specific, since in the groups immunized with MPyVLPs loaded
onto DCs and co-injected with CpG 80% of the mice developed
tumors (p=ns) (Table 1).
The D2F2/PSA cell line was tested for PSA expression using
immunoblot after passage in vivo, in both immunized and non-
immunized mice, and was shown to still express PSA (data not
shown).
PSA-specific CD4
+ and CD8
+ cells are induced by PSA-
MPyVLP immunization
The induction of PSA-specific CD4
+ and CD8
+ cells after
vaccination with PSA-MPyVLPs was assayed for by using three
different methods, which all were repeated at least twice.
Splenocytes from immunized and non-immunized mice, stimulat-
ed with recombinant PSA or PSA peptides (CD4 or CD8-
restricted), were analysed for IFNc secretion by ELISpot,
intracellular IFNc production by flow cytometry, or for prolifer-
ation by BrdU-incorporation assay.
When assayed by ELISpot using recombinant PSA, significantly
more PSA-specific secretion of IFNc was induced after immuni-
zation with PSA-MPyVLPs alone (p,0.05), PSA-MPyVLPs on
DCs (p,0.01), and PSA-MPyVLPs on DCs with CpG (p,0.01) as
compared to splenocytes from non-immunized mice or mice
immunized with MPyVLPs (Figure 3A and B). When assaying by
ELISpot using CD4- and CD8 specific peptides, it was also
possible to show that both CD4
+ (p,0.01) and CD8
+ (p,0.05)
PSA-specific cells were observed after PSA-MPyVLP immuniza-
tion (Figure 3C). However, after immunization with PSA-
MPyVLPs loaded DCs a significant production of PSA-specific
CD8
+ cells (p,0.05) was observed, while the PSA-specific CD4
+
response was weaker (Figure 3C).
PSA-MPyVLP immunization was also shown to induce
significantly more CD8
+ IFNc-producing cells (p,0.05) when
analysed by flow cytometry after a five day in vitro stimulation
period (Figure 4A), as well as significantly more proliferation of
Figure 4. IFNc production and proliferation of PSA-specific
CD4
+ and CD8
+ cells. (A) Intracellular IFNc staining. PSA-MPyVLP
immunization induced significantly more PSA-specific CD8
+ cells
compared to non-immunized mice (p ,0.05) after a five day in vitro
stimulation period. Shown are representative flow cytometric dot-plots
from two experiments with three mice per group. Numbers in upper
right quadrants represent mean percentage IFNc-producing cells out of
all CD4
+ or CD8
+ cells +/2 S.D. for both experiments performed. Values
from cells stimulated with control peptide NP118-126 have been
subtracted. (B) In vitro proliferation assay. PSA-MPyVLP immunization
induced significant proliferation of PSA-specific CD4
+ cells compared to
non-immunized mice (p ,0.01). Shown are representative flow
cytometric dot-plots from two experiments with three mice per group.
Numbers in upper right quadrants represent mean percentage CD4
+ or
CD8
+ cells out of all proliferating cells +/2 S.D. for both experiments
performed. Values from cells stimulated with control protein HSA have
been subtracted. p values calculated using Student’s t-test (* =
p,0.05).
doi:10.1371/journal.pone.0023828.g004
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+ cells (p,0.01) compared to non-immunized
mice (Figure 4B).
PSA-MPyVLP immunization does not induce production
of PSA-specific IgG antibodies
To assay for the induction of PSA-specific IgG antibodies, sera from
PSA-MPyVLP immunized mice were analysed by an ELISA coated
with recombinant PSA. No anti-PSA IgG antibodies were detected in
any of the immunized or non-immunized mice (data not shown).
Vaccination with DCs loaded with PSA-MPyVLPs induces
lower titres of anti-VP1 antibodies than vaccination with
PSA-MPyVLPs alone
To detect anti-VP1 IgG antibodies, an ELISA coated with
MPyVLPs was performed on sera from vaccinated and control
mice. Immunization with PSA-MPyVLPs and CpG induced 8-fold
higher titres of anti-VP1 IgG compared to immunization with the
same type of VLPs loaded onto DCs and injected with CpG
(p,0.0001) (Figure 5).
Discussion
In this study the possibility to produce MPyVLPs carrying
human full-length PSA and the ability to use these PSA-MPyVLPs
together with CpG and DCs to immunize against a PSA positive
tumor (D2F2/PSA) in BALB/c mice was demonstrated. In
addition, cellular and humoral immune responses after different
immunization protocols were examined in vitro.
PSA-MPyVLPs were demonstrated both to have an intact
capsid and to contain the VP2/3-PSA fusion protein. These results
are in line with previous results showing that it is possible to
produce chimeric MPyVLPs carrying large proteins, without
disrupting the capsid structure, which makes them useful as
immunogens [29,32].
When PSA-MPyVLPs were used alone, or together with CpG
for immunization, there was a decrease in outgrowth of D2F2/
PSA. In comparison to the previously very efficient immunization
with another tumor antigen (Her2), with Her2-MPyVLPs [29], the
obtained effect after immunizing with PSA-MPyVLPs alone or
with CpG was clearly weaker. The reason for this difference could
be due to properties of the antigens, e.g. PSA is secreted from the
cells, while Her2 is a surface antigen. However, when loading
PSA-MPyVLPs onto DCs as well as adding CpG, the immuni-
zation efficiency improved, which was also in line with previous
findings for Her2-MPyVLPs [32]. It has been suggested that
loading of VLPs onto DCs could induce maturation of the DCs.
However, in spite of extensive efforts we have never demonstrated
the upregulation of maturation markers, such as MHC II, CD80
or CD86, when murine DCs were incubated with Her2-MPyVLPs
in vitro [32].
IFNc-secreting cells were activated after immunization with
PSA-MPyVLPs, as demonstrated by ELISpot where splenocytes
were stimulated with recombinant PSA, and loading of PSA-
MPyVLPs onto DCs improved the response as compared to
immunization with PSA-MPyVLPs alone. However, the response
measured with ELISpot after immunization with PSA-MPyVLPs
on DCs injected with CpG was weaker than the response after
immunization without CpG. This seems rather surprising, but has
been demonstrated previously, both by our group (unpublished
data) and by Lubaroff et al [39]. The latter reported in 2006 that
co-administration of an adenovirus-PSA vaccine and CpG ODN
increased tumor protection in a mouse model of prostate cancer
and at the same time decreased cytotoxic T cell activity in vitro.
By ELISpot, stimulating splenocytes with PSA CD4- or CD8
restricted peptides, we could also demonstrate that immunization
with PSA-MPyVLPs induced production of both CD4
+ and CD8
+
IFNc-secreting cells. Loading of PSA-MPyVLPs onto DCs
resulted in significant induction of PSA-specific CD8
+ cells,
compared to mice immunized with MPyVLPs on DCs as well as
non-immunized mice. The fact that both CD4
+ and CD8
+ cells
are induced was also supported by our FACS data and are in line
with previous results in a similar model. In that model, BALB/c
mice were depleted of different immune cells before, or during,
immunization with Her2-MPyVLPs, and there we could show that
CD4
+ and CD8
+ cells could act separately to protect mice from
tumor outgrowth, while depletion of both subsets of cells
completely abrogated protection [34].
PSA-specific IgG antibodies were not demonstrated after
immunization with PSA-MPyVLPs. This could possibly be
explained by the fact that PSA is fused to VP2/3, which are
assumed to be on the inside of the VLPs, making it inaccessible to
Figure 5. Anti-VP1 antibodies in sera. Loading of PSA-MPyVLPs onto DCs decreased the anti-VP1 IgG antibody response 8-fold compared to
immunization with PSA-MPyVLPs alone (p ,0.0001). Error bars represent S.D. p values calculated using Student’s t-test (** p,0.01).
doi:10.1371/journal.pone.0023828.g005
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studies, where anti-Her2 antibodies were not produced after
immunization with Her2-MPyVLPs [29].
Furthermore, DC-vaccination with PSA-MPyVLPs reduced the
antibody response to VP1 eight-fold compared to the response
obtained by immunizing with PSA-MPyVLPs alone. This parallels
the situation observed after immunizing with Her2-MPyVLPs
alone or together with DCs, where the addition of DCs reduced
the antibody response to VLPs six-fold [32]. Loading of VLPs onto
DCs could thus be an advantage for prime-boost therapy, since
fewer neutralizing antibodies are present.
In conclusion, immunization with PSA-MPyVLPs, loaded onto
DCs and co-injected with CpG, induces an efficient immune
response against PSA, which protects BALB/c mice from
outgrowth of a PSA-expressing tumor. This immune response
includes both CD4
+ and CD8
+ cells specific for PSA, in the
absence of an antibody response to PSA. Furthermore, loading of
VLPs onto DCs reduces the anti-VLP antibody response,
favourable for prime-boost therapies.
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